Liquidia CorporationOverview
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of innovative therapies for pulmonary arterial hypertension (PAH), a rare and severe form of high blood pressure that affects the arteries in the lungs. The company’s main product targets